Education
About Us
Working with TipRanks
Follow Us
SQZ Biotechnologies (SQZB)
OTHER OTC:SQZB
SQZB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.02 - $0.09
Previous CloseN/A
Volume166.00
Average Volume (3M)758.00
Market Cap
$825.75K
Enterprise ValueN/A
Total Cash (Recent Filing)$10.19M
Total Debt (Recent Filing)$21.47M
Price to Earnings (P/E)―
Beta0.84
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.43
Shares Outstanding29,491,125
10 Day Avg. Volume962
30 Day Avg. Volume758
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
SQZB FAQ
What was SQZ Biotechnologies’s price range in the past 12 months?
SQZ Biotechnologies lowest stock price was $0.02 and its highest was $0.09 in the past 12 months.
What is SQZ Biotechnologies’s market cap?
SQZ Biotechnologies’s market cap is $825.75K.
When is SQZ Biotechnologies’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were SQZ Biotechnologies’s earnings last quarter?
Currently, no data Available
Is SQZ Biotechnologies overvalued?
According to Wall Street analysts SQZ Biotechnologies’s price is currently Overvalued.
Does SQZ Biotechnologies pay dividends?
SQZ Biotechnologies does not currently pay dividends.
What is SQZ Biotechnologies’s EPS estimate?
SQZ Biotechnologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SQZ Biotechnologies have?
SQZ Biotechnologies has 29,491,125 shares outstanding.
What happened to SQZ Biotechnologies’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of SQZ Biotechnologies?
Currently, no hedge funds are holding shares in SQZB
Company Description
SQZ Biotechnologies
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Technical Analysis
Biodexa Pharmaceuticals
―
TNF Pharmaceuticals
―
Salarius Pharmaceuticals
―
Scinai Immunotherapeutics
―
Oragenics
―
Ownership Overview
―
Insiders
―
Mutual Funds
5.49% Other Institutional Investors
94.51% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---